OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company’s scientific Co-Founder, David Sinclair, Ph.D., has been selected for the 2014 TIME 100, TIME’s annual list of the 100 most influential people in the world. Dr. Sinclair’s extensive research on aging and the key role of mitochondria (the energy source for all cells) contributed to OvaScience’s foundational egg precursor cell (EggPC SM) technology platform. The Company expects to launch its first fertility product, AUGMENT SM, in international in vitro fertilization (IVF) clinics in 2014. AUGMENT is designed to improve egg quality and the success of IVF by enhancing mitochondrial function.
“We congratulate Dr. Sinclair on his recognition by TIME for his groundbreaking research on aging, which is enabling the development of new treatments for conditions of aging, such as infertility,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Our team at OvaScience is working with Dr. Sinclair to gain further insights about the impact of aging on egg quality as we continue to develop treatments for female infertility.”
Dr. Sinclair is a Professor in the Department of Genetics at Harvard Medical School and a con-joint Professor in the Department of Physiology and Pharmacology at the University of New South Wales. Dr. Sinclair was recruited to Harvard Medical School in 1999 where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in energy metabolism, mitochondria, neurodegeneration, and cancer. Dr. Sinclair is the co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging and a Senior Scholar of the Ellison Medical Foundation.
Dr. Sinclair has published more than 126 scientific papers. His December 2013 paper in Cell underscored the critical role of mitochondrial function in aging, and described certain molecules that can improve mitochondrial function, to which OvaScience has exclusive rights in fertility. Dr. Sinclair is the 2014 Australian Society for Medical Research (ASMR) medalist, an award which recognizes his career contributions to medical research, and an honor shared by past Nobel Prize winners. He is also the co-founder of several biotechnology companies and is on the scientific advisory board of several others.Earlier in his career, Dr. Sinclair worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast and the role of Sir2 in DNA repair and aging. He obtained his Ph.D. in Biochemistry and Molecular Genetics at the University of New South Wales, Sydney in 1995.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts